CVS Health delivered one of the widest earnings beats in its recent history Wednesday and raised full-year guidance across the board. The stock fell about 6% anyway.
Adjusted earnings came in at $2.58 a share against the $1.85 analysts expected, with revenue of $106.10 billion. That topped the $100.11 billion consensus and marked roughly 7% growth from a year earlier. Net income reached $3.0 billion, up from $1.0 billion in the same quarter of 2025, while operating income nearly doubled to $4.7 billion, helped by the absence of prior-year litigation charges.
The company lifted full-year adjusted earnings guidance to $7.90 to $8.10 a share from $7.30 to $7.50, and raised revenue guidance to at least $414 billion from at least $405 billion.
Shares dropped nearly 6% to around $98 on the news.
Why the Selloff
The disconnect comes down to what happens after this year.
Investors have grown skeptical about the 2027 earnings picture, with particular concern about anticipated client departures at Caremark, the pharmacy benefit manager that anchors the Health Services division. A quarter this strong makes the comparison harder rather than easier: the higher 2026 lands, the steeper any 2027 step-down looks.
Caremark is under structural pressure from several directions at once — regulatory scrutiny of the pharmacy benefit model, employers rethinking their arrangements, and manufacturers building direct-to-patient channels that route around benefit managers entirely.
Caremark also recently reached a settlement with the Federal Trade Commission involving rebate reforms and transparency commitments.
Segment by Segment
Health Services, which houses Caremark, generated $51.8 billion in revenue, up 11.5%. CVS credited pharmacy drug mix and branded drug inflation, offset partly by ongoing pricing concessions to clients. That last phrase is the one to watch — revenue is growing while the terms are getting worse.
The insurance segment housing Aetna posted $37.54 billion, up 3.5%, with the medical benefit ratio improving to 87.4% from 89.9%. Insurers across the sector have struggled with elevated medical costs as Medicare Advantage patients return for procedures deferred during the pandemic, though many now appear better equipped to manage the trend after cutting membership, trimming benefits and exiting unprofitable markets.
Pharmacy and consumer wellness came in at $33.82 billion, up about 0.7%. Adjusted operating income for that unit rose 10.2% to $1.48 billion on core pharmacy strength and acquired Rite Aid assets, despite regulatory price reductions and reimbursement pressure.
The Turnaround Behind the Numbers
The results reflect continued progress on a broader restructuring that has involved cutting $2 billion in costs, closing underperforming stores, changing leadership and reducing costs inside Medicare Advantage plans. Improved medical-cost trends at Aetna, a more profitable drug mix and bonus payments tied to highly rated government health plans drove the quarterly profit.
Through the first half, profit reached $5.9 billion on revenue of $206.5 billion, against $2.8 billion and $193.5 billion in the same period last year.
The company is also pushing automation into its administrative operations. CVS is deploying agentic AI across call center interactions and claims processing at both Aetna and Caremark, and says its second-generation Aetna claims tool has cut processing time by more than 20% on complex claims requiring manual review.
The Weight-Loss Play
Wednesday’s other announcement was strategic rather than financial. CVS unveiled a collaboration with Eli Lilly making Zepbound and the new weight-loss pill Foundayo available to eligible patients through the CVS Health app by early in the fourth quarter, covering both insured patients and those paying cash.
The company also launched expanded GLP-1 support across its pharmacies and MinuteClinic, including a $29 virtual visit, and participates in the Medicare GLP-1 Bridge program offering certain drugs at $50 monthly through 2027.
CVS now operates roughly 9,000 stores and serves approximately 27 million medical members — the scale argument for why a company under pressure at the benefit-manager layer still has a defensible position at the counter.
JBizNews Desk | New York
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.